| 1 | survival | 48,921 |
| 2 | survivals | 237 |
| 3 | overall-survival | 8 |
| 4 | time-to-next-treatment | 5 |
| 5 | 13/59 | 4 |
| 6 | medication-adherence | 4 |
| 7 | 0502 | 3 |
| 8 | event-free-survival | 3 |
| 9 | gfds | 3 |
| 10 | relapse/metastasis | 3 |
| 11 | time-to-goal | 3 |
| 12 | 26/1440 | 2 |
| 13 | chromatism | 2 |
| 14 | disease-recurrence | 2 |
| 15 | pooled-prevalence | 2 |
| 16 | signifificantly | 2 |
| 17 | -1.64cm | 1 |
| 18 | 102/1419 | 1 |
| 19 | 106/151 | 1 |
| 20 | 175/754 | 1 |
| 21 | 255/493 | 1 |
| 22 | 290/2101 | 1 |
| 23 | 330/468 | 1 |
| 24 | 4-dimethylaminocinnamaldehyde | 1 |
| 25 | 46/1115 | 1 |
| 26 | 7/2498 | 1 |
| 27 | 8/2315 | 1 |
| 28 | 9828 | 1 |
| 29 | asymptomatics | 1 |
| 30 | avg-patency | 1 |
| 31 | biochemical-free | 1 |
| 32 | bp-control | 1 |
| 33 | cholesterol-loweringtherapy | 1 |
| 34 | compliance/attendance | 1 |
| 35 | csbe | 1 |
| 36 | cvd-diabetes | 1 |
| 37 | deltasas | 1 |
| 38 | diagnosability | 1 |
| 39 | dyphagia | 1 |
| 40 | efficacy-analyses | 1 |
| 41 | efficaey | 1 |
| 42 | fertility.there | 1 |
| 43 | follow-up3 | 1 |
| 44 | freedom-from-bos | 1 |
| 45 | freedom-from-disease-progression | 1 |
| 46 | freedom-from-lrr | 1 |
| 47 | hiace | 1 |
| 48 | holder-pasteurisation | 1 |
| 49 | ili-program | 1 |
| 50 | intensity/magnitude | 1 |
| 51 | lymphaticum | 1 |
| 52 | manoeuvers | 1 |
| 53 | meta-arr | 1 |
| 54 | number-willing-to-treat | 1 |
| 55 | nut-like | 1 |
| 56 | patients'prognosis | 1 |
| 57 | pfs/efs | 1 |
| 58 | physio-therapy | 1 |
| 59 | post-priming | 1 |
| 60 | potentization | 1 |
| 61 | ps+/-value | 1 |
| 62 | qol-scale | 1 |
| 63 | responder/remission | 1 |
| 64 | rr=210 | 1 |
| 65 | severity/chronicity | 1 |
| 66 | surivall | 1 |
| 67 | surviva | 1 |
| 68 | survival-associated | 1 |
| 69 | survival-hazard | 1 |
| 70 | survival.however | 1 |
| 71 | survival/time-to-progression | 1 |
| 72 | survivalos | 1 |
| 73 | transplant/vad-free | 1 |
| 74 | treatment-packets | 1 |
| 75 | vfd-60 | 1 |
| 76 | vo₂-uptake | 1 |
| 77 | wmd=-0.45 | 1 |
| 78 | wmd=0.35 | 1 |
| 1 | -1.64cm | 1 |
| 2 | 0502 | 3 |
| 3 | 102/1419 | 1 |
| 4 | 106/151 | 1 |
| 5 | 13/59 | 4 |
| 6 | 175/754 | 1 |
| 7 | 255/493 | 1 |
| 8 | 26/1440 | 2 |
| 9 | 290/2101 | 1 |
| 10 | 330/468 | 1 |
| 11 | 4-dimethylaminocinnamaldehyde | 1 |
| 12 | 46/1115 | 1 |
| 13 | 7/2498 | 1 |
| 14 | 8/2315 | 1 |
| 15 | 9828 | 1 |
| 16 | asymptomatics | 1 |
| 17 | avg-patency | 1 |
| 18 | biochemical-free | 1 |
| 19 | bp-control | 1 |
| 20 | cholesterol-loweringtherapy | 1 |
| 21 | chromatism | 2 |
| 22 | compliance/attendance | 1 |
| 23 | csbe | 1 |
| 24 | cvd-diabetes | 1 |
| 25 | deltasas | 1 |
| 26 | diagnosability | 1 |
| 27 | disease-recurrence | 2 |
| 28 | dyphagia | 1 |
| 29 | efficacy-analyses | 1 |
| 30 | efficaey | 1 |
| 31 | event-free-survival | 3 |
| 32 | fertility.there | 1 |
| 33 | follow-up3 | 1 |
| 34 | freedom-from-bos | 1 |
| 35 | freedom-from-disease-progression | 1 |
| 36 | freedom-from-lrr | 1 |
| 37 | gfds | 3 |
| 38 | hiace | 1 |
| 39 | holder-pasteurisation | 1 |
| 40 | ili-program | 1 |
| 41 | intensity/magnitude | 1 |
| 42 | lymphaticum | 1 |
| 43 | manoeuvers | 1 |
| 44 | medication-adherence | 4 |
| 45 | meta-arr | 1 |
| 46 | number-willing-to-treat | 1 |
| 47 | nut-like | 1 |
| 48 | overall-survival | 8 |
| 49 | patients'prognosis | 1 |
| 50 | pfs/efs | 1 |
| 51 | physio-therapy | 1 |
| 52 | pooled-prevalence | 2 |
| 53 | post-priming | 1 |
| 54 | potentization | 1 |
| 55 | ps+/-value | 1 |
| 56 | qol-scale | 1 |
| 57 | relapse/metastasis | 3 |
| 58 | responder/remission | 1 |
| 59 | rr=210 | 1 |
| 60 | severity/chronicity | 1 |
| 61 | signifificantly | 2 |
| 62 | surivall | 1 |
| 63 | surviva | 1 |
| 64 | survival | 48,921 |
| 65 | survival-associated | 1 |
| 66 | survival-hazard | 1 |
| 67 | survival.however | 1 |
| 68 | survival/time-to-progression | 1 |
| 69 | survivalos | 1 |
| 70 | survivals | 237 |
| 71 | time-to-goal | 3 |
| 72 | time-to-next-treatment | 5 |
| 73 | transplant/vad-free | 1 |
| 74 | treatment-packets | 1 |
| 75 | vfd-60 | 1 |
| 76 | vo₂-uptake | 1 |
| 77 | wmd=-0.45 | 1 |
| 78 | wmd=0.35 | 1 |
| 1 | rr=210 | 1 |
| 2 | 26/1440 | 2 |
| 3 | vfd-60 | 1 |
| 4 | 290/2101 | 1 |
| 5 | 106/151 | 1 |
| 6 | 0502 | 3 |
| 7 | 255/493 | 1 |
| 8 | follow-up3 | 1 |
| 9 | 175/754 | 1 |
| 10 | 46/1115 | 1 |
| 11 | 8/2315 | 1 |
| 12 | wmd=0.35 | 1 |
| 13 | wmd=-0.45 | 1 |
| 14 | 9828 | 1 |
| 15 | 330/468 | 1 |
| 16 | 7/2498 | 1 |
| 17 | 102/1419 | 1 |
| 18 | 13/59 | 4 |
| 19 | dyphagia | 1 |
| 20 | surviva | 1 |
| 21 | survival-associated | 1 |
| 22 | survival-hazard | 1 |
| 23 | csbe | 1 |
| 24 | hiace | 1 |
| 25 | compliance/attendance | 1 |
| 26 | pooled-prevalence | 2 |
| 27 | medication-adherence | 4 |
| 28 | disease-recurrence | 2 |
| 29 | intensity/magnitude | 1 |
| 30 | 4-dimethylaminocinnamaldehyde | 1 |
| 31 | transplant/vad-free | 1 |
| 32 | biochemical-free | 1 |
| 33 | vo₂-uptake | 1 |
| 34 | nut-like | 1 |
| 35 | qol-scale | 1 |
| 36 | fertility.there | 1 |
| 37 | ps+/-value | 1 |
| 38 | post-priming | 1 |
| 39 | time-to-goal | 3 |
| 40 | survival | 48,921 |
| 41 | event-free-survival | 3 |
| 42 | overall-survival | 8 |
| 43 | surivall | 1 |
| 44 | bp-control | 1 |
| 45 | ili-program | 1 |
| 46 | -1.64cm | 1 |
| 47 | chromatism | 2 |
| 48 | lymphaticum | 1 |
| 49 | freedom-from-disease-progression | 1 |
| 50 | survival/time-to-progression | 1 |
| 51 | responder/remission | 1 |
| 52 | holder-pasteurisation | 1 |
| 53 | potentization | 1 |
| 54 | survival.however | 1 |
| 55 | meta-arr | 1 |
| 56 | freedom-from-lrr | 1 |
| 57 | deltasas | 1 |
| 58 | asymptomatics | 1 |
| 59 | gfds | 3 |
| 60 | efficacy-analyses | 1 |
| 61 | cvd-diabetes | 1 |
| 62 | pfs/efs | 1 |
| 63 | relapse/metastasis | 3 |
| 64 | patients'prognosis | 1 |
| 65 | survivals | 237 |
| 66 | freedom-from-bos | 1 |
| 67 | survivalos | 1 |
| 68 | manoeuvers | 1 |
| 69 | treatment-packets | 1 |
| 70 | number-willing-to-treat | 1 |
| 71 | time-to-next-treatment | 5 |
| 72 | avg-patency | 1 |
| 73 | efficaey | 1 |
| 74 | signifificantly | 2 |
| 75 | physio-therapy | 1 |
| 76 | cholesterol-loweringtherapy | 1 |
| 77 | severity/chronicity | 1 |
| 78 | diagnosability | 1 |